scientifiC Board

Hugh P.J. Bennett  Ph.D. -  Professor Dept. of Medicine,  Canadian Pacific Chair in Biotechnology,  Director of the Sheldon Biotechnology Institute,  McGill University Montreal, Quebec. Hugh has extensive expertise in protein and peptide isolation and structure-function relationships.  As Director of the Sheldon Biotechnology Institute, he has current knowledge of the most discerning purification and analytical methodologies as applied to biomolecules.    

Michael Strong M.D. F.R.C.P.C - Professor and Dean of the Department of Clinical Neurological Sciences University of Western Ontario. Mike is the past chair of the health professional advisory committee of the ALS Society of Canada. He has extensive experience both as a clinician and basic research scientist and is an acknowledged authority on ALS.

H.A. Robertson Ph.D.  - Harry graduated from the Universities of Western Ontario (B.A., M.Sc.) and Cambridge (Ph.D.) and is now Professor Emeritus of Pharmacology at Dalhousie University where he was Carnegie and Rockefeller Professor and Head of the Department of Pharmacology for a decade.  He is a fellow of the Royal Society of Canada.  He was the First Neurofortis Visiting Professor at Lund University in Sweden and is also an Adjunct Professor at the University of Prince Edward Island. Dr. Robertson is co-founder of the Brain Repair Center (BRC) at Dalhousie University, and it’s first Director of Research.  The BRC He is best known for discovering the role of the immediate early gene c-fos in brain and for his work on Parkinson’s and Huntington’s disease.  He is currently involved in several clinical trials on transplantation and early diagnosis in Parkinson’s disease.

R.A.R. Tasker Ph.D.  - Andrew is Professor of Neuropharmacology at UPEI’s Atlantic Veterinary College is a Fellow of the Canadian Academy of Health Sciences. A former Associate Dean, Research at UPEI, Dr. Tasker is currently the Founding Director of the newly constructed Atlantic Centre for Comparative Biomedical Research and one of six founding scientists of NoNO Inc., a Toronto-based drug discovery company.  An internationally acknowledged authority of the neurotoxicology of domoic acid and other glutamatergic ligands he specializes in behavioral models appropriate to the study of epilepsy, stroke and cognitive decline.